Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
10/2005
10/25/2005US6958333 N'-(isoindolino[3,2-b]perhydro-1,3-oxazin-5-on-9-yl)-N-(pyridin-2-yl) urea, for example; cyclin-dependent kinase inhibitors; colon cancer treatment
10/25/2005US6958332 Treating an interleukin-12 overproduction-related disorder; treating rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/25/2005US6958328 5H-indeno(1,2-b)pyridine-3-carboxylic acid,4-phenyl-2-amino-5-oxo-, ethyl ester; adenosine receptor antagonists, phosphodiesterase inhibitors; neurodegenerative disorders, AIDS; antiinflammatory agent
10/25/2005CA2332461C New benzenesulfonamide derivatives, their method of preparation and the pharmaceutical compositions containing them
10/25/2005CA2304974C 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
10/25/2005CA2261725C Piperidine and piperazine derivatives and their use as muscarinic antagonists
10/25/2005CA2110454C 1,5,7-trisubstituted indoline compounds for the treatment of dysuria
10/23/2005CA2504796A1 Polymorphs of pantoprazole sodium salt and process for the preparation thereof
10/21/2005CA2504582A1 Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer
10/21/2005CA2504401A1 Drug delivery systems for the prevention of neointimal hyperlasia
10/20/2005WO2005097791A1 Inhibitors of iap
10/20/2005WO2005097781A1 Quinines-4-substituted derivatives, method and intermediates for the preparation thereof and pharmaceutical compositions containing said derivatives
10/20/2005WO2005097779A1 Diarylamine derivatives as calcium channel blockers
10/20/2005WO2005097778A1 Tetrahydrobenzazepines as histamine h3 receptor ligands
10/20/2005WO2005097776A1 Composition comprising an optically-active monomeric compound, method implementing said composition, monomeric compound, polymer comprising same, and use thereof
10/20/2005WO2005097775A1 Piperidine derivates for the treatment of chemokines mediared disease
10/20/2005WO2005097774A1 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
10/20/2005WO2005097768A2 Novel gamma secretase inhibitors
10/20/2005WO2005097758A1 Certain triazole-based compounds, compositions, and uses thereof
10/20/2005WO2005097756A1 Nitrogenous heterocycle derivative and organic electroluminescent element employing the same
10/20/2005WO2005097752A1 Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions
10/20/2005WO2005097750A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005WO2005097746A2 2-propene-1-ones as hsp 70 inducers
10/20/2005WO2005097740A1 Histamine h3 receptor agents, preparation and therapeutic uses
10/20/2005WO2005097738A1 Novel sulfonamide derivative
10/20/2005WO2005097713A1 Fluoridation method
10/20/2005WO2005097203A2 Serum protein conjugates of ion channel modulating compounds and uses thereof
10/20/2005WO2005097137A2 Advanced quinazoline based protein kinase inhibitors
10/20/2005WO2005097136A1 Biaryl substituted pyrazinones as sodium channel blockers
10/20/2005WO2005097134A2 Quinazoline based protein kinase inhibitors
10/20/2005WO2005097128A1 1,4-bis-n-oxide azaanthracenediones and the use thereof
10/20/2005WO2005097112A2 Ion channel modulators
10/20/2005WO2005097107A2 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005WO2005096692A2 Crystalline forms of mizolastine, production methods thereof and pharmaceutical compositions containing same
10/20/2005WO2005085236A3 Caspase inhibitors and uses thereof
10/20/2005WO2005070919A8 N-type calcium channel blockers
10/20/2005WO2005070891A3 Compounds and methods of use
10/20/2005WO2005066129A3 Bis-pyridino containing compounds for use in the treatment of cns pathologies
10/20/2005WO2005061450A3 Hiv protease inhibiting sulfonamides
10/20/2005WO2005055715A3 Insecticidal n-(heteroarylalkyl) alkanediamine derivatives
10/20/2005WO2005046590A3 Methods for synthesizing quinolinone compounds
10/20/2005WO2005035525A3 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/20/2005WO2005030794B1 Hemiasterlin derivatives and uses thereof
10/20/2005WO2004071460A3 Cyclic derivatives as modulators of chemokine receptor activity
10/20/2005US20050234238 8-(Biaryl)quinoline pde4 inhibitors
10/20/2005US20050234236 Process for preparing pyridazinone compounds
10/20/2005US20050234117 and geranylgeranyltransferase inhibitor; 3-chloromethyl-4-cyanobenzyl-5 methyl triazole; antitumor agents; prevent membrane attachment of protein p21ras and block aberrant growth of ras-transformed tumors; capable to inhibit prenylation of Ras proteins, both at enzymatic and cellular level
10/20/2005US20050234109 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234104 Dabigatran etexilate mesylate polymorph, crystalline form of a prodrug used for post-operative prophylaxis of deep vein thrombosis and the prevention of a stroke; stability; solubility; reproduciblity; hydrophobic; pharmacological potency; low amorphization during grinding and compression
10/20/2005US20050234103 Crystalline forms of rabeprazole sodium
10/20/2005US20050234101 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
10/20/2005US20050234099 Microsomal triglyceride transfer protein (MTP) inhibitor (S)-2-[(4'-Isopropoxybiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid {[(4-fluoro-benzyl)methylcarbamoyl]phenylmethyl}amide; treating obesity
10/20/2005US20050234098 antitumor, anticarcinogenic agents; cytotoxic activity and angiogensis inhibitors; leukemia, colorectal cancer; orally
10/20/2005US20050234094 Inhibition of protein kinases with piridinylimidazoles
10/20/2005US20050234085 1-methyl-3 beta -hydroxymethyl-6-methoxy-1,2,3,4,4a alpha ,5,10, 10a beta -octahydrobenzo[q]quinoline; decrease on the intraocular pressure; glaucoma and myopia; excellent tolerability, and a long duration of action
10/20/2005US20050234083 Diamino-pyrimidines and their use as angiogenesis inhibitors
10/20/2005US20050234082 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/20/2005US20050234080 Mitotic kinesin inhibitors
10/20/2005US20050234069 Novel polymorphs of imatinib mesylate
10/20/2005US20050234067 e.g. 1-(3,4-dibromo-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4.5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes
10/20/2005US20050234065 Dipeptidyl peptidase-IV inhibitors
10/20/2005US20050234064 2-(4-Methoxyphenyl)-amino-),3-(aminocarbonyl-)quinoxaline; janus(JAK) kinase inhibitors;spleen tyrosine kinase(SYK) inhibitors; glycogen synthase-3(GSK-3) kinase inhibitors; immunocompetance; antiinflammatory agents; antiallergens; autoimmune diseases; antiproliferative agents; respiratory disorders
10/20/2005US20050234062 Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234059 4-(5-Methyl-2-phenyl-pyrimidin-4-yl)-1H-pyrrole-2 carboxylic acid (2-hydroxy-1-(S)-phenyl-ethyl)-amide; Mitogen-activated protein kinase inhibitor; anticarcinogenic, antiinflammatory agent,neurodegenerative disorders, restenosis, antidiabetic, antiallergen, and cardiovascular disease
10/20/2005US20050234057 1-Phenylpiperidin-3-one derivatives and processes for the preparation thereof
10/20/2005US20050234055 Pyrazole derivative
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050234047 Respiratory syncytial virus replication inhibitors
10/20/2005US20050234046 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
10/20/2005US20050234045 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
10/20/2005US20050234044 Cyclic amine derivatives and methods of use
10/20/2005US20050234042 Organic compounds
10/20/2005US20050234039 Substituted lactams as inhibitors of Abeta protein production
10/20/2005US20050234030 Modulators of CRTH2, COX-2 and FAAH
10/20/2005US20050233979 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid
10/20/2005US20050233234 Electroluminescent platinum compounds and devices made with such compounds
10/20/2005CA2563033A1 Novel gamma secretase inhibitors
10/20/2005CA2562780A1 Nucleic acid melting analysis with saturation dyes
10/20/2005CA2562399A1 Diphenyl - indol-2-on compounds and their use in the treatment of cancer
10/20/2005CA2562371A1 Diarylamine derivatives as calcium channel blockers
10/20/2005CA2561967A1 Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
10/20/2005CA2561801A1 Sulfonamides and uses thereof
10/20/2005CA2561621A1 Quinolone carboxylic acid derivatives for treatment of hyperproliferative conditions
10/20/2005CA2561280A1 Substituted pyridones as inhibitors of poly(adp-ribose) polymerase (parp)
10/20/2005CA2560954A1 Certain triazole-based compounds, compositions, and uses thereof
10/20/2005CA2560796A1 Biaryl substituted pyrazinones as sodium channel blockers
10/20/2005CA2560162A1 Inhibitors of iap
10/20/2005CA2557721A1 Ion channel modulators
10/19/2005EP1586571A1 Dipeptidyl peptidase inhibitors
10/19/2005EP1586565A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
10/19/2005EP1586322A2 Compositions for inhibition of anglogenesis
10/19/2005EP1585827A2 Modulation of protein functionalities
10/19/2005EP1585743A1 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
10/19/2005EP1585735A1 Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
10/19/2005EP1585734A2 Anti-inflammatory medicaments
10/19/2005EP1585727A1 Indoles useful in the treatment of androgen-receptor related diseases
10/19/2005EP1585522A2 Quinazolinones as potassium channel modulators
1 ... 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 ... 1080